Literature DB >> 4050707

Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure.

J R Benotti, L J Lesko, J E McCue, J S Alpert.   

Abstract

The acute hemodynamic effects and pharmacokinetics of bolus intravenous milrinone administration were assessed in 13 patients with severe congestive heart failure. Serial hemodynamics were measured and blood samples were obtained to determine plasma milrinone concentration and calculation of pharmacokinetic variables after administration of milrinone at 12.5, 25, 50 and 75 micrograms/kg, allowing at least 6 hours to elapse between consecutive milrinone doses. At each dose milrinone effected prompt but very short-lived increases in cardiac output and left ventricular stroke work and decreases in pulmonary artery pressure, right atrial pressure and systemic and pulmonary vascular resistance in a non-dose-dependent fashion. Pulmonary artery wedge pressure decreased in a dose-related manner. Heart rate increased significantly after the 75-micrograms/kg dose and mean arterial pressure decreased significantly only after the 50- and 75-micrograms/kg milrinone dose. The time-dependent decline in plasma milrinone concentration was biexponential and log linear, conforming to an open 2-compartment model of drug distribution and elimination. Mean plasma milrinone clearance (+/- standard error) was 0.15 +/- 0.03 liters/min/kg, volume of distribution was 0.35 +/- 0.02 liters/kg and mean elimination half-life was 1.7 hours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4050707     DOI: 10.1016/0002-9149(85)91036-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Use of milrinone in critically ill children.

Authors:  Teresa Bishara; Winnie T W Seto; Angela Trope; Christopher S Parshuram
Journal:  Can J Hosp Pharm       Date:  2010-11

3.  Pharmacokinetics of piroximone (MDL 19.205) in healthy volunteers.

Authors:  K D Haegele; G G Belz; T T Meinicke; P J Schechter
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

5.  Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.

Authors:  Winnie Vogt
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

6.  Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis.

Authors:  Shigeyuki Yamashita; Tokiko Suzuki; Keisuke Iguchi; Takuya Sakamoto; Kengo Tomita; Hiroki Yokoo; Mari Sakai; Hiroki Misawa; Kohshi Hattori; Toshi Nagata; Yasuhide Watanabe; Naoyuki Matsuda; Naoki Yoshimura; Yuichi Hattori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-20       Impact factor: 3.000

7.  Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Tsunehisa Tsubokawa; Syuichi Ishizuka; Kyoko Fukumoto; Kazuyuki Ueno; Ken Yamamoto
Journal:  J Anesth       Date:  2012-10-23       Impact factor: 2.078

Review 8.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 9.  The pharmacokinetics and pharmacodynamics of newer inotropic agents.

Authors:  M L Rocci; H Wilson
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 10.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.